Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
$329.99
$12.58B1.18832,048 shs5 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.34
-0.7%
$1.32
$1.21
$2.04
$1.06B1.343.87 million shs1.97 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.31
+1.8%
$24.81
$11.16
$27.64
$1.08B0.48900,910 shs694,660 shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
$53.01
$53.01
$25.02
$65.00
$2.91B0.431.07 million shsN/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%+0.37%+1.50%-4.93%-2.17%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-1.31%-5.53%-8.29%+5.24%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.022 of 5 stars
3.50.00.04.42.33.30.6
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.1006 of 5 stars
2.21.00.03.92.12.50.6
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.75105.22% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4413.45% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VIE, KRTX, OPK, TARO, and PCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.49$0.07 per share19.62$2.00 per share0.67
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.54$4.40 per share5.30$16.86 per share1.38
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
Viela Bio, Inc. stock logo
VIE
Viela Bio
$50M58.26N/AN/A$7.14 per share7.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.07N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/A

Latest VIE, KRTX, OPK, TARO, and PCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/A
19.51
19.49

Institutional Ownership

CompanyInstitutional Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%
Viela Bio, Inc. stock logo
VIE
Viela Bio
46.98%

Insider Ownership

CompanyInsider Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
13.80%
Viela Bio, Inc. stock logo
VIE
Viela Bio
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable
Viela Bio, Inc. stock logo
VIE
Viela Bio
16654.95 millionN/ANot Optionable

Recent News About These Companies

BETDAQ app download
dc vs punjab 2022
Khelo India Khelo lucky 3 result today
777 Win Sooter
RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar
Roche takes on Alexion as FDA approves satralizumab in NMOSD
Regenxbio Names Mitchell Chan CFO
2024 Fire Awards: Meet this year's Ablaze honorees

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.34 -0.01 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.31 +0.41 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$23.31 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Viela Bio stock logo

Viela Bio NASDAQ:VIE

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.